Precision and personalized medicine has already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.
The digital transformation of the healthcare industry is driving the development of new diagnostics and therapeutics for precision and personalized medicine. For example, advances in biomarker testing with next-generation sequencing (NGS) are improving patient selection, use of artificial intelligence (AI) in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies, such as robotics, cloud, and the Internet of Things (IoT), is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Drug pricing and reimbursement will continue to be the greatest challenge to the adoption of precision and personalized medicines, as governments look to reduce drug prices to increase market access during a time of macroeconomic turbulence, while drug developers argue that price drops stifle innovation. Traditional approaches to reimbursement do not work for drugs such as cell and gene therapies, and only the adoption of novel models will help to balance market access with profitability.
The digital transformation of the healthcare industry is driving the development of new diagnostics and therapeutics for precision and personalized medicine. For example, advances in biomarker testing with next-generation sequencing (NGS) are improving patient selection, use of artificial intelligence (AI) in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies, such as robotics, cloud, and the Internet of Things (IoT), is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Drug pricing and reimbursement will continue to be the greatest challenge to the adoption of precision and personalized medicines, as governments look to reduce drug prices to increase market access during a time of macroeconomic turbulence, while drug developers argue that price drops stifle innovation. Traditional approaches to reimbursement do not work for drugs such as cell and gene therapies, and only the adoption of novel models will help to balance market access with profitability.
Key Highlights
- This report consolidates the publisher's latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the precision and personalized medicine space, as well as providing insights into the leading players and future disruptors across the value chain, and providing insights into key drugs and markets from the publisher's Pharma Intelligence Center
- The report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for precision and personalized medicines.
Scope
- A focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting precision and personalized medicine, and a review of the ways in which these trends will accelerate or hinder precision and personalized medicine.
- Industry analysis and market forecast for different therapies within precision and personalized medicine up to 2029.
- Case studies providing in-depth insight into some of the most recent and most influential developments in precision and personalized medicine, from recently approved gene therapies to new AI platforms to accelerate the development of new personalized drugs.
- Review of leaders and disruptors across the precision and personalized medicine value chain, covering diagnostics, therapeutics, and services.
- Thematic scorecard for drug development ranking companies on their investment in the top ten themes impacting the industry, one of which being precision and personalized medicine.
Reasons to Buy
- Understand the key trends accelerating or hindering the precision and personalized medicine space.
- See market forecasts for different therapies within precision and personalized medicine up to 2029.
- Understand recent and influential developments in precision and personalized medicine.
- Review of leaders and disruptors across the precision and personalized medicine value chain.
Table of Contents
- Players
- Thematic Briefing
- Trends
- Industry Analysis
- Value Chain
- Companies
- Drug Development Scorecard
- Abbreviations
- Further Reading
- About the Authors
- Our Thematic Research Methodology
- Table 1: Healthcare trends impacting precision and personalized medicine
- Table 2: Technology trends impacting precision and personalized medicine
- Table 3: Macroeconomic trends impacting precision and personalized medicine
- Table 4: Regulatory trends impacting precision and personalized medicine
- Table 5: Recent strategic partnerships in precision and personalized medicine
- Table 6: Recent funding deals in precision and personalized medicine
- Table 7: Recent M&As in precision and personalized medicine
- Table 8: Examples of public companies in precision and personalized medicine
- Table 9: Examples of private companies in precision and personalized medicine
Figure 1: Examples of players in precision and personalized medicine and where they sit in the value chain
Figure 2: Forecast sales of precision and personalized medicines by molecule type, 2022-29
Figure 3: Social media discussions related to precision and personalized medicine has increased since 2019
Figure 4: Word cloud with trends related to precision and personalized medicine social media discussions
Figure 5: Examples of popular posts related to precision and personalized medicine
Figure 6: The precision and personalized medicine value chain
Figure 7: Examples of diagnostics providers in precision and personalized medicine
Figure 8: Examples of cell therapy developers in precision and personalized medicine
Figure 9: Examples of gene therapy developers in precision and personalized medicine
Figure 10: Examples of mRNA drug developers in precision and personalized medicine
Figure 11: Examples of targeted therapy drug developers in precision and personalized medicine
Figure 12: Examples of service providers in precision and personalized medicine
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche
- Illumina
- Agilent Technologies
- Abbott
- Myriad Genetics
- Thermo Fisher Scientific
- Guardant Health
- Tempus Labs
- Ocean Genomics
- Nicheri Biosciences
- Certis Oncology Solutions
- Novartis
- Merck & Co
- Johnson & Johnson
- Moderna
- Gilead Sciences
- CRISPR Therapeutics
- Bristol Myers Squibb
- Roche
- Sarepta Therapeutics
- Alaunos Therapeutics
- BrainStorm Cell Therapeutics
- OncoSec Medical
- Rocket Pharmaceuticals
- Vor Biopharma
- IQVIA
- Charles River Laboratories
- Lonza
- WuXi AppTec
- Syneos Health
- AmerisourceBergen
- Catalent
- Parexel
- CellCarta
- Multiply Lab
- Almac Group
- Kelsius
- Alynlyam Pharmaceutical
- Legend Biotech
- Gamida Cell
- Bio4t2
- Akkure Genomics
- Deep6 AI
- MatchMiner
- Dassault Systèmes
- Alcaris Theranostics
- Quinten Health
- Qiagen
- PharmaLogic
- Perspective Therapeutics
- NH TherAguix
- Clarity Pharmaceuticals
- Cytiva
- Multiply Labs
- Takeda
- CSL Behring
- AstraZeneca
- Brainvectis
- Bluebird Bio
- Intellia Therapeutics
- Regeneron
- Mesoblast
- Replimune
- Verve Therapeutics
- Quell Therapeutics
- Genethon
- Hansa Biopharma
- SonoThera
- Arsenal Bioscience
- Tempus
- Elevate Bio
- Personalis
- CARsgen Therapeutics
- Amgen
- Ideaya Biosciences
- Vertex Pharmaceuticals
- Immatics
- Myeloid Therapeutics
- Prime Medicine
- Bayer
- Mammoth Biosciences
- Kate Therapeutics
- Mozart Therapeutics
- Acepodia
- ReNAgade Therapeutics
- Ray Therapeutics
- Convergent Therapeutics
- ImmuneBridge
- TORL BioTherapeutics
- CARGO Therapeutics
- Chroma Medicine
- Resalis Therapeutics
- IASO Biotherapeutics
- Metagenomi
- CG Oncology
- Tessa Therapeutics
- Engimmue Therapeutics
- Swedish Orphan Biovitrum
- Astellas Pharma
- Sartorius Stedim Biotech
- Viatris
- Catalent
- Galapagos
- ViaCyte
- Bora Pharmaceuticals
- UCB
- Krystal Biotech
- BioNTech
- Alphabet
- OpenAI
- C4XD
- Circulogene
- 10xGenomics
- SomaLogic
- Benevolent AI
- Exscientia
- Allscripts
- Atara Biotherapeutics
- JCR Pharmaceuticals
- Orchard Therapeutics
- Longeveron
- Daiichi Sankyo
- Silence Therapeutics
- Arrowhead Pharmaceuticals
- Poseida Therapeutics
- Beam Therapeutics
- Stemirna Therapeutics
- GreenLight Biosciences
- NeoCura Bio-Medical Technology
- Ono Pharmaceutical
- TG Therapeutics
- Viridian Therapeutics
- Celldex Therapeutics
- Exilis
- Tango Therapeutics
- Oncolytics Biotech.
